Alvocidib (Flavopiridol)

Mechanism of action

From the NCI Drug Dictionary: A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.
Route: PO

Diseases for which it is used

• Acute myeloid leukemia
• Chronic lymphocytic leukemia (CLL/SLL)

History of changes in FDA indication

• 4/13/2007: Granted orphan status for treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.
• 4/23/2014: Granted orphan designation for the treatment of patients with acute myeloid leukemia (AML)

Also known as

• Code names: HMR 1275, L-868275